PharmTech Weekly Roundup—July 17, 2026

Some of this week’s highlights include the fact that the use of artificial intelligence is facing harder questions of governance and data quality. Regulators in the United States and the European Union are streamlining pathways to market. And on the plant floor, precision engineering still decides whether a product ships on cost and on spec.

In regulatory news this week, the FDA finalized guidance, replacing a bioequivalence standard for topical corticosteroids and clarifying meeting procedures for OTC monograph sponsors. And the European Medicines Agency deepened ties with the EU's innovation agency to help small biopharma developers engage regulators earlier and head off late-stage manufacturing surprises.

And late last week, the FDA proposed letting distributed “hub-and-spoke” manufacturing networks register as one establishment, while closing a registration gap for foreign API suppliers.

In other news, GSK's AZUR-1 trial showed dostarlimab alone produced a sustained complete response in a rectal cancer subtype, raising the possibility that some patients could avoid chemo, radiation, and surgery altogether.

Digital Technologies Move Forward

AI and other digital technologies have received a lot of attention this week on PharmTech.com.

Brian Drapeau, founder of GXPFrame, argued compliant AI in pharma isn't a content-generation problem, but rather a governance problem, requiring an “applicability engine” that keeps humans in control of downstream training and evidence.

In the latest episode of Manufacturing Intelligence, Richard Jaenisch of Open Biopharma, explains how Roche's GPU buildout and Sanofi's talent-first strategy target different AI bottlenecks, and that workforce trust not hardware is where most companies are stuck.

Manish Garg's midyear check-in finds AI reshaping pipelines toward high-value therapies, tariffs accelerating supply chain diversification, and the FDA's coming NDC-12 rule as a systems overhaul companies aren't ready for.

Rahul Mittal of Dr Reddy’s Laboratory makes the case that automation's next phase is connecting fragmented plant data through digital twins and electronic batch records so people can make better decisions.

And Arcana Life Sciences’ Remco Munnik, in an update on his 2026 industry predictions, reports EU regulatory data reform is progressing, but AI adoption is still bottlenecked by weak data governance.

When it comes to quality considerations, Jeffrey Mocny of Abzena and Anna McMahon of Cellares, spoke with PharmTech’s sister publication, BioPharm International, about how risk-based quality management should be embedded into process design from day one to speed up biopharma development.

And Henrik Johanning, of Epista Life Science, provided PharmTech with a midyear industry review. According to Johanning, Annex 1 is driving real capital investment in contamination control, while AI governance is clearer in principle than in practice.

Manufacturing Challenges

For drug manufacturing, Jordan Xu of Drofen Machinery Equipment, detailed how real-time force monitoring and dimensional verification assist high-speed pen injector lines in protecting costly drug cartridges while hitting above 99.5% first-pass yield.

And James Golden of CRB warned that oligonucleotide manufacturing's massive solvent volumes can push facilities into high-hazard building classifications, driving outsized costs.

Taken together, this week's stories point to an industry maturing in place: AI is being pushed to prove its governance and data foundations, regulators are removing friction without lowering the bar, and on the plant floor, the margin for error is still measured in fractions of a percent.

That's this week's roundup. For the full stories, visit PharmTech.com.